APO Research
Talk to an analyst

APO RESEARCH · REPORT

Obstetrics and Gynecology Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Obstetrics and Gynecology Drugs Market Outlook and Growth Opportunities 2026

30 December 2025194 pages

Choose your research edition.

Industry ResearchObstetrics and Gynecology Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Obstetrics and Gynecology Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Obstetrics and Gynecology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Obstetrics and Gynecology Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Obstetrics and Gynecology Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Obstetrics and Gynecology Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Obstetrics and Gynecology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Obstetrics and Gynecology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Obstetrics and Gynecology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Obstetrics and Gynecology Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Obstetrics and Gynecology Drugs market include Abbott, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Bayer and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Obstetrics and Gynecology Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Obstetrics and Gynecology Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Obstetrics and Gynecology Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Obstetrics and Gynecology Drugs market.

Obstetrics and Gynecology Drugs Segment by Company

Abbott

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Bayer

Amgen

Abbvie

AstraZeneca

TherapeuticsMD

Lupin

GlaxoSmithKline

Ferring

Obstetrics and Gynecology Drugs Segment by Type

Hormonal Therapy

Non-Hormonal Therapy

Obstetrics and Gynecology Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Obstetrics and Gynecology Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Obstetrics and Gynecology Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Obstetrics and Gynecology Drugs key companies, revenue, market share, and recent developments.

3. To split the Obstetrics and Gynecology Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Obstetrics and Gynecology Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Obstetrics and Gynecology Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Obstetrics and Gynecology Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Obstetrics and Gynecology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Obstetrics and Gynecology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Obstetrics and Gynecology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Obstetrics and Gynecology Drugs industry.

Chapter 3: Detailed analysis of Obstetrics and Gynecology Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Obstetrics and Gynecology Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Obstetrics and Gynecology Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Obstetrics and Gynecology Drugs Industry Trends Table 2. Obstetrics and Gynecology Drugs Industry Drivers Table 3. Obstetrics and Gynecology Drugs Industry Opportunities and Challenges Table 4. Obstetrics and Gynecology Drugs Industry Restraints Table 5. Global Obstetrics and Gynecology Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Obstetrics and Gynecology Drugs Revenue Share by Company (2021-2026) Table 7. Global Obstetrics and Gynecology Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Obstetrics and Gynecology Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Obstetrics and Gynecology Drugs Company, Product Type & Application Table 10. Global Obstetrics and Gynecology Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Obstetrics and Gynecology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Hormonal Therapy Table 15. Significant Companies of Non-Hormonal Therapy Table 16. Global Obstetrics and Gynecology Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Obstetrics and Gynecology Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Obstetrics and Gynecology Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Obstetrics and Gynecology Drugs Sales Value Share by Type (2021-2026) Table 20. Global Obstetrics and Gynecology Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Pharmacies Table 22. Significant Companies of Online Pharmacies Table 23. Significant Companies of Retail Pharmacies Table 24. Global Obstetrics and Gynecology Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Obstetrics and Gynecology Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Obstetrics and Gynecology Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Obstetrics and Gynecology Drugs Sales Value Share by Application (2021-2026) Table 28. Global Obstetrics and Gynecology Drugs Sales Value Share by Application (2027-2032) Table 29. Global Obstetrics and Gynecology Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Obstetrics and Gynecology Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Obstetrics and Gynecology Drugs Sales Value Share by Region (2021-2026) Table 32. Global Obstetrics and Gynecology Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Obstetrics and Gynecology Drugs Sales Value Share by Region (2027-2032) Table 34. Global Obstetrics and Gynecology Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Obstetrics and Gynecology Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Obstetrics and Gynecology Drugs Sales Value Market Share by Country (2021-2026) Table 37. Global Obstetrics and Gynecology Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Obstetrics and Gynecology Drugs Sales Value Market Share by Country (2027-2032) Table 39. Abbott Company Information Table 40. Abbott Business Overview Table 41. Abbott Obstetrics and Gynecology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Abbott Obstetrics and Gynecology Drugs Product Portfolio Table 43. Abbott Recent Development Table 44. Johnson & Johnson Company Information Table 45. Johnson & Johnson Business Overview Table 46. Johnson & Johnson Obstetrics and Gynecology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Johnson & Johnson Obstetrics and Gynecology Drugs Product Portfolio Table 48. Johnson & Johnson Recent Development Table 49. Novartis Company Information Table 50. Novartis Business Overview Table 51. Novartis Obstetrics and Gynecology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Novartis Obstetrics and Gynecology Drugs Product Portfolio Table 53. Novartis Recent Development Table 54. Merck Company Information Table 55. Merck Business Overview Table 56. Merck Obstetrics and Gynecology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Merck Obstetrics and Gynecology Drugs Product Portfolio Table 58. Merck Recent Development Table 59. Roche Company Information Table 60. Roche Business Overview Table 61. Roche Obstetrics and Gynecology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Roche Obstetrics and Gynecology Drugs Product Portfolio Table 63. Roche Recent Development Table 64. Eli Lilly Company Information Table 65. Eli Lilly Business Overview Table 66. Eli Lilly Obstetrics and Gynecology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Eli Lilly Obstetrics and Gynecology Drugs Product Portfolio Table 68. Eli Lilly Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Obstetrics and Gynecology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pfizer Obstetrics and Gynecology Drugs Product Portfolio Table 73. Pfizer Recent Development Table 74. Bayer Company Information Table 75. Bayer Business Overview Table 76. Bayer Obstetrics and Gynecology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bayer Obstetrics and Gynecology Drugs Product Portfolio Table 78. Bayer Recent Development Table 79. Amgen Company Information Table 80. Amgen Business Overview Table 81. Amgen Obstetrics and Gynecology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Amgen Obstetrics and Gynecology Drugs Product Portfolio Table 83. Amgen Recent Development Table 84. Abbvie Company Information Table 85. Abbvie Business Overview Table 86. Abbvie Obstetrics and Gynecology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Abbvie Obstetrics and Gynecology Drugs Product Portfolio Table 88. Abbvie Recent Development Table 89. AstraZeneca Company Information Table 90. AstraZeneca Business Overview Table 91. AstraZeneca Obstetrics and Gynecology Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. AstraZeneca Obstetrics and Gynecology Drugs Product Portfolio Table 93. AstraZeneca Recent Development Table 94. TherapeuticsMD Company Information Table 95. TherapeuticsMD Business Overview Table 96. TherapeuticsMD Obstetrics and Gynecology Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. TherapeuticsMD Obstetrics and Gynecology Drugs Product Portfolio Table 98. TherapeuticsMD Recent Development Table 99. Lupin Company Information Table 100. Lupin Business Overview Table 101. Lupin Obstetrics and Gynecology Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Lupin Obstetrics and Gynecology Drugs Product Portfolio Table 103. Lupin Recent Development Table 104. GlaxoSmithKline Company Information Table 105. GlaxoSmithKline Business Overview Table 106. GlaxoSmithKline Obstetrics and Gynecology Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. GlaxoSmithKline Obstetrics and Gynecology Drugs Product Portfolio Table 108. GlaxoSmithKline Recent Development Table 109. Ferring Company Information Table 110. Ferring Business Overview Table 111. Ferring Obstetrics and Gynecology Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Ferring Obstetrics and Gynecology Drugs Product Portfolio Table 113. Ferring Recent Development Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Obstetrics and Gynecology Drugs Product Image Figure 2. Global Obstetrics and Gynecology Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Obstetrics and Gynecology Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Obstetrics and Gynecology Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Hormonal Therapy Image Figure 8. Non-Hormonal Therapy Image Figure 9. Global Obstetrics and Gynecology Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Obstetrics and Gynecology Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Obstetrics and Gynecology Drugs Sales Value Share by Type (2021-2032) Figure 12. Hospital Pharmacies Image Figure 13. Online Pharmacies Image Figure 14. Retail Pharmacies Image Figure 15. Global Obstetrics and Gynecology Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Obstetrics and Gynecology Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Obstetrics and Gynecology Drugs Sales Value Share by Application (2021-2032) Figure 18. Global Obstetrics and Gynecology Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Obstetrics and Gynecology Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Obstetrics and Gynecology Drugs Sales Value (2021-2032) & (US$ Million) Figure 21. North America Obstetrics and Gynecology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Obstetrics and Gynecology Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Obstetrics and Gynecology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Obstetrics and Gynecology Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Obstetrics and Gynecology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Obstetrics and Gynecology Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. South America Obstetrics and Gynecology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Obstetrics and Gynecology Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Obstetrics and Gynecology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Hormonal Therapy
  • Non-Hormonal Therapy
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Abbott
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Bayer
  • Amgen
  • Abbvie
  • AstraZeneca
  • TherapeuticsMD
  • Lupin
  • GlaxoSmithKline
  • Ferring

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Obstetrics and Gynecology Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Obstetrics and Gynecology Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Obstetrics and Gynecology Drugs Market Dynamics
  1. 2.1 Obstetrics and Gynecology Drugs Industry Trends
  2. 2.2 Obstetrics and Gynecology Drugs Industry Drivers
  3. 2.3 Obstetrics and Gynecology Drugs Industry Opportunities and Challenges
  4. 2.4 Obstetrics and Gynecology Drugs Industry Restraints
3 Obstetrics and Gynecology Drugs Market by Company
  1. 3.1 Global Obstetrics and Gynecology Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Obstetrics and Gynecology Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Obstetrics and Gynecology Drugs Company Ranking (2024-2026)
  4. 3.4 Global Obstetrics and Gynecology Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Obstetrics and Gynecology Drugs Company Product Type and Application
  6. 3.6 Global Obstetrics and Gynecology Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Obstetrics and Gynecology Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Obstetrics and Gynecology Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Obstetrics and Gynecology Drugs Market by Type
  1. 4.1 Obstetrics and Gynecology Drugs Type Introduction
  2. 4.1.1 Hormonal Therapy
  3. 4.1.2 Non-Hormonal Therapy
  4. 4.2 Global Obstetrics and Gynecology Drugs Sales Value by Type
  5. 4.2.1 Global Obstetrics and Gynecology Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Obstetrics and Gynecology Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Obstetrics and Gynecology Drugs Sales Value Share by Type (2021-2032)
5 Obstetrics and Gynecology Drugs Market by Application
  1. 5.1 Obstetrics and Gynecology Drugs Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Obstetrics and Gynecology Drugs Sales Value by Application
  6. 5.2.1 Global Obstetrics and Gynecology Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Obstetrics and Gynecology Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Obstetrics and Gynecology Drugs Sales Value Share by Application (2021-2032)
6 Obstetrics and Gynecology Drugs Regional Value Analysis
  1. 6.1 Global Obstetrics and Gynecology Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Obstetrics and Gynecology Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Obstetrics and Gynecology Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Obstetrics and Gynecology Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Obstetrics and Gynecology Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Obstetrics and Gynecology Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Obstetrics and Gynecology Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Obstetrics and Gynecology Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Obstetrics and Gynecology Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Obstetrics and Gynecology Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Obstetrics and Gynecology Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Obstetrics and Gynecology Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Obstetrics and Gynecology Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Obstetrics and Gynecology Drugs Sales Value Share by Country, 2025 VS 2032
7 Obstetrics and Gynecology Drugs Country-level Value Analysis
  1. 7.1 Global Obstetrics and Gynecology Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Obstetrics and Gynecology Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Obstetrics and Gynecology Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Obstetrics and Gynecology Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Obstetrics and Gynecology Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Obstetrics and Gynecology Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Obstetrics and Gynecology Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Obstetrics and Gynecology Drugs Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Obstetrics and Gynecology Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Obstetrics and Gynecology Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Obstetrics and Gynecology Drugs Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Obstetrics and Gynecology Drugs Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Obstetrics and Gynecology Drugs Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Obstetrics and Gynecology Drugs Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Obstetrics and Gynecology Drugs Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Obstetrics and Gynecology Drugs Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 Abbvie
  56. 8.10.1 Abbvie Company Information
  57. 8.10.2 Abbvie Business Overview
  58. 8.10.3 Abbvie Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Abbvie Obstetrics and Gynecology Drugs Product Portfolio
  60. 8.10.5 Abbvie Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Obstetrics and Gynecology Drugs Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 TherapeuticsMD
  68. 8.12.1 TherapeuticsMD Company Information
  69. 8.12.2 TherapeuticsMD Business Overview
  70. 8.12.3 TherapeuticsMD Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 TherapeuticsMD Obstetrics and Gynecology Drugs Product Portfolio
  72. 8.12.5 TherapeuticsMD Recent Developments
  73. 8.13 Lupin
  74. 8.13.1 Lupin Company Information
  75. 8.13.2 Lupin Business Overview
  76. 8.13.3 Lupin Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Lupin Obstetrics and Gynecology Drugs Product Portfolio
  78. 8.13.5 Lupin Recent Developments
  79. 8.14 GlaxoSmithKline
  80. 8.14.1 GlaxoSmithKline Company Information
  81. 8.14.2 GlaxoSmithKline Business Overview
  82. 8.14.3 GlaxoSmithKline Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GlaxoSmithKline Obstetrics and Gynecology Drugs Product Portfolio
  84. 8.14.5 GlaxoSmithKline Recent Developments
  85. 8.15 Ferring
  86. 8.15.1 Ferring Company Information
  87. 8.15.2 Ferring Business Overview
  88. 8.15.3 Ferring Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Ferring Obstetrics and Gynecology Drugs Product Portfolio
  90. 8.15.5 Ferring Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst